Peptide Index

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. It has shown notable healing properties in preclinical studies, particularly for tendons, ligaments, and gut tissue.

recovery · research-only

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that extends GH pulses by acting on the GHRH receptor. It has real human pharmacodynamic data showing dose-dependent GH and IGF-1 increases, making its evidence base stronger than most peptides in this space, though outcome trials for body composition or recovery don't exist. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

hormonal · category-2

Epithalon is a synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is known for the claim that it activates telomerase and elongates telomeres in cell culture. Animal studies show life-span extension in rodents and reduced tumor incidence. Human data is limited to small biomarker studies from Russian institutions. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

longevity · research-only

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma whose concentration declines with age. It is the only compound on this site with meaningful topical human trial data, primarily for skin aging and wound healing. Systemic injectable use has much thinner evidence. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

skincare · research-only

Ipamorelin is a selective growth hormone secretagogue that stimulates pulsatile GH release without spiking cortisol or appetite. It has solid mechanistic and animal data, small human pharmacodynamic studies, and one discontinued therapeutic program. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

hormonal · category-2

KPV is a tripeptide corresponding to the three C-terminal amino acids of alpha-melanocyte-stimulating hormone. It retains much of alpha-MSH's anti-inflammatory activity through melanocortin receptor signaling. Its primary evidence base is animal models of inflammatory bowel disease. It is notable for surviving gastrointestinal conditions better than most peptides, making oral delivery plausible for gut-targeted effects. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

recovery · research-only

LL-37 is the only human cathelicidin, a 37-amino-acid peptide with broad-spectrum antimicrobial activity and immunomodulatory effects. It is naturally produced by neutrophils and epithelial cells as part of innate immunity. Its in vitro antimicrobial data is extensive; human trial data for injectable therapeutic use is essentially absent. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

recovery · research-only

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on the central nervous system to enhance sexual arousal. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women — the only peptide on this list with a current US drug approval. Compounded versions remain subject to regulatory restrictions.

hormonal · fda-approved

Selank is a synthetic heptapeptide derived from the immune peptide tuftsin, developed and approved in Russia for anxiety disorders. It has a plausible GABAergic mechanism, clinical trials from Russian institutions, and a growing nootropic community following. Independent Western replication is essentially absent. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

performance · research-only

Semax is a synthetic heptapeptide derived from the ACTH(4-7) fragment, developed in Russia and approved there for cognitive impairment and stroke recovery. Its most studied mechanism is BDNF upregulation in the hippocampus. Evidence comes from Russian institutions, animal studies, and small clinical trials; independent Western replication is essentially absent. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

performance · research-only

TB-500 is a synthetic fragment of Thymosin Beta-4, a protein that regulates actin in nearly every human cell. It has broad animal evidence for tissue repair and angiogenesis, minimal human data outside of ophthalmic trials, and is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

recovery · category-2

Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid thymic peptide with the broadest clinical trial record of any compound on this site. It is approved in over 35 countries under the brand name Zadaxin for hepatitis B, hepatitis C, and as a chemotherapy adjuvant. It is not FDA-approved and is sold as a research compound in the United States. It is one of 12 peptides targeted in the 2026 US regulatory reclassification process.

recovery · research-only